---
document_datetime: 2025-07-18 14:24:09
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tolura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tolura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4908077
conversion_datetime: 2025-12-26 10:58:54.429395
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tolura

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 17/07/2025                          |                                             | SmPC and PL                      | To change the description \"angiotensin II receptor |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000279934   | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To change the   | antagonists\" to \"angiotensin II receptor blockers\" throughout the annexes. The change follows assessment of the same change to the reference product, Micardis (EMA/VR/0000242970). To update the SmPC and PL following assessment of the same change to the reference product, Micardis (WS/2489), including: - An update of Sections 4.2, 4.4 and 4.9 of the SmPC with information related to the removal of telmisartan by haemodialisis. - An update of Section 4.7 of the SmPC, replacing the terms 'dizziness' and 'drowsiness' by 'syncope' and 'vertigo' to align with ADR table in section 4.8 of the SmPC. - An update of Section 4.8 of the SmPC in order to include 'hyponatremia' to the list of adverse drug reactions (ADRs) with frequency 'rare', based on post marketing data and literature - An update of Section 5.3 of the SmPC regarding the effect of telmisartan on male and female fertility   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | and 'drowsiness' by 'syncope' and 'vertigo' to align with ADR table in section 4.8 of the SmPC. - An update of Section 4.8 of the SmPC in order to include 'hyponatremia' to the list of adverse drug reactions (ADRs) with frequency 'rare', based on post marketing data and literature - An update of Section 5.3 of the SmPC regarding the effect of telmisartan on male and female fertility Additionally, the MAH took the opportunity to implement editorial changes to align with the PI of the reference product, to combine the SmPC for all strengths, to align with the QRD template, and to add information regarding the excipient sodium throughout the PI based on the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000268268 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the                                                                                                                                                                                                                                                                                                                                                                                                      | 30/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |             |                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000247066 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH - Accepted To updated sections 4.4 and 4.8 of the SmPC to add new safety information regarding intestinal angioedema following PRAC recommendation EMA/PRAC/499603/2024; EPITT 20104. The package leaflet is updated accordingly. In addition the MAH has taken the opportunity to make minor editorial corrections in several translations. | 18/03/2025 | SmPC and PL | To updated sections 4.4 and 4.8 of the SmPC to add new safety information regarding intestinal angioedema following PRAC recommendation EMA/PRAC/499603/2024; EPITT 20104. The package leaflet is updated accordingly. In addition the MAH has taken the opportunity to make minor editorial corrections in several translations. |